ATLANTA – March 30, 2021 – Wayne H. Elowe, co-chair of the Life Sciences and Medical Technology Group at global law firm Greenberg Traurig, LLP, and co-chair of the firm’s Atlanta Corporate Practice, led the Greenberg Traurig team representing Tiancheng Investment Management and its portfolio company Bio Products Laboratory, in the sale of 25 U.S.–based plasma donation centers to Grifols S.A. Greenberg Traurig Shareholder Stacey Orr Gallant was also a key member of the transaction team.
As part of the $370 million transaction, Grifols’ subsidiary, Biomat USA, acquired 25 U.S.-based plasma donation centers from BPL Plasma Inc., a subsidiary of Bio Products Laboratory Holdings Limited, a global supplier of high-quality plasma derived medicines headquartered in the United Kingdom and with plasma collection centers across the United States. The transaction has received the applicable regulatory clearances.
Elowe concentrates his practice on international mergers and acquisitions, joint ventures, strategic investments and alliances, licensing, and technology transactions. He regularly represents life sciences companies in connection with structuring and negotiating complex relationships involving the acquisition, licensing, sharing, development, and monetization of various technology-driven assets and platforms. Elowe has represented clients in more than 50 countries in North America, Asia, Europe, the Middle East, and Latin America - including over 27 years of experience doing business in and out of China. In addition, he serves as outside general counsel to numerous multinational clients and is actively involved with their senior executive teams in developing and implementing strategy-concerning matters, such as new business and product initiatives, as well as corporate matters and litigation.
About Greenberg Traurig’s Corporate Practice: Greenberg Traurig’s Corporate Practice comprises more than 450 lawyers in the United States, Europe, Asia, the Middle East and Latin America who regularly advise public and privately held companies, entrepreneurs and investment funds on global mergers and acquisitions, corporate restructurings, private equity and venture capital, underwritten and syndicated offerings, commercial finance and syndicated lending, cross-border transactions, and general corporate matters. The group’s industry experience includes transactions in a wide range of fields, from the pharmaceutical, medical devices, and life sciences fields, to representations involving clients in the aviation, banking, consumer products, energy, food and beverage, health care, manufacturing, media, technology, and telecommunications sectors.
About Greenberg Traurig’s Life Sciences & Medical Technology Group: Greenberg Traurig’s Life Sciences & Medical Technology Group advises clients ranging from startups to large multinational public companies to leading research institutions. The group’s attorneys work closely with clients, providing innovative legal counsel to help them achieve their objectives – from discovery through commercialization and product marketing.
About Greenberg Traurig, LLP: Greenberg Traurig, LLP (GT), has approximately 2200 attorneys in 40 locations in the United States, Latin America, Europe, Asia, and the Middle East. GT has been recognized for its philanthropic giving, diversity, and innovation, and is consistently among the largest firms in the U.S. on the Law360 400 and among the Top 20 on the Am Law Global 100. The firm is net carbon neutral with respect to its office energy usage and Mansfield Rule 3.0 Certified. Web: www.gtlaw.com